Skip to main content
editorial
. 2021 Jan 28;10(1):1–9. doi: 10.1159/000514194

Table 3.

Dose reduction status due to adverse events during sorafenib treatment by treatment period

2008–2012 period (n = 154) 2013–2017 period (n = 184) p value
Dose reduction to 400 mg/day 113 (75.3) 157 (86.4) 0.009
Re-escalation to 800 mg/day 34/113 (30.2) 35/157 (22.0) 0.341
Dose reduction to 200 mg/day 21 (18.2) 56 (35.2) <0.001
Re-escalation to 400 mg/day 15/21 (71.4) 34/56 (60.7) 0.691

Data are expressed as frequencies (percentage). Modified from Ref. [7].